MorqPreg: Pregnancy With Morquio Syndrome - What Are Patients' Perspectives and Has ERT Changed Them?

Sponsor
Emory University (Other)
Overall Status
Completed
CT.gov ID
NCT03150069
Collaborator
BioMarin Pharmaceutical (Industry)
18
1
15.2
1.2

Study Details

Study Description

Brief Summary

The present study seeks to interview women with Morquio A and Morquio B syndrome, to explore their concerns surrounding pregnancy and the impact of ERT on their perspectives, in comparison with the control group of Morquio B subjects for whom no ERT treatment exists.

Interviews will be conducted by a health psychologist, in-person or over the telephone. Data will be analyzed using MAXQDA 12.0 software and Grounded Theory. Differences in thematic trends between Morquio A subjects, for whom treatment exists, and a control group of Morquio B subjects, for whom there is no treatment, will be compared.

Condition or Disease Intervention/Treatment Phase
  • Other: Interview

Detailed Description

The present study seeks to interview women with Morquio A and Morquio B syndrome themselves, to explore and discover their perspectives and concerns surrounding pregnancy and having biological children, the impact of the advent of ERT for Morquio A on their perspectives and concerns in comparison with the control group of Morquio B subjects for whom no ERT treatment exists, as well as what each group is being told by the medical community and others in their lives in this regard.

Interviews will be conducted by a health psychologist, either in-person or over the telephone. We will interview 1) those women with Morquio syndrome who are known to have been pregnant and 2) those women with Morquio syndrome who have not been pregnant and/or chose to adopt children. All information will be kept confidential, except as in accordance with Georgia law relating to reporting of child or elder abuse, suicidal and/or homicidal intent.

Data will be analyzed using MAXQDA 12.0 software to develop code which can be used to describe and compare the data using Grounded Theory. Differences in thematic trends between Morquio A subjects, for whom treatment exists, and a control group of Morquio B subjects, for whom there is no treatment, will be compared.

Study Design

Study Type:
Observational
Actual Enrollment :
18 participants
Observational Model:
Cohort
Time Perspective:
Cross-Sectional
Official Title:
Pregnancy With Morquio Syndrome - What Are Patients' Perspectives and Has ERT Changed Them?
Actual Study Start Date :
May 10, 2017
Actual Primary Completion Date :
Aug 17, 2018
Actual Study Completion Date :
Aug 17, 2018

Arms and Interventions

Arm Intervention/Treatment
Morquio A / Biological Mothers

Women with Morquio A who have biological children

Other: Interview
In-person or telephone in-depth interview

Morquio A / No Biological Children

Women with Morquio A who do not have biological children (both adoptive mothers and non-mothers)

Other: Interview
In-person or telephone in-depth interview

Morquio B / Biological Mothers

Women with Morquio B who have biological children

Other: Interview
In-person or telephone in-depth interview

Morquio B / No Biological Children

Women with Morquio B who do not have biological children (both adoptive mothers and non-mothers)

Other: Interview
In-person or telephone in-depth interview

Outcome Measures

Primary Outcome Measures

  1. Completion of in-depth interview [Approximately 1 hour]

    Completion of in-depth interview

Eligibility Criteria

Criteria

Ages Eligible for Study:
15 Years to 100 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  1. Documented clinical diagnosis of either MPS IVA or MPS IVB, based on clinical signs and symptoms, documented reduced fibroblast or leukocyte GALNS enzyme activity or genetic testing confirming diagnosis.

  2. Subject is at least 15 years old.

  3. Subject is female.

  4. Subject is fluent enough in English to complete in-depth interview with PI.

Exclusion Criteria:
  1. Patient has a clinically significant disease other than Morquio which would confound the effects of Morquio upon study variables.

  2. Any condition that, in the view of the Investigator, places the patient at high risk of poor compliance or of not completing the study.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Emory University Decatur Georgia United States 30033

Sponsors and Collaborators

  • Emory University
  • BioMarin Pharmaceutical

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Nadia Ali, PhD, Principal Investigator, Emory University
ClinicalTrials.gov Identifier:
NCT03150069
Other Study ID Numbers:
  • IRB00088777
First Posted:
May 11, 2017
Last Update Posted:
Jan 20, 2021
Last Verified:
Jan 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Nadia Ali, PhD, Principal Investigator, Emory University
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jan 20, 2021